CYTO (Altamira Therapeutics Ltd.) Enterprise Value-to-Revenue Coefficient

Public company logo of Auris Medical (CYTO)

Altamira Therapeutics (CYTO) has weakened its primary cash flow due to a strategic pivot toward RNA therapy and the divestment of previous assets. Meanwhile, the production of nasal agents and RNA compositions has been delegated to European contractors. The company is expanding its workforce with experts specializing in drug delivery to the brain and ear. The EV/Sales multiple visualizes the debt-free market value, where the metric indicates the status of the current business valuation.

CYTO Altamira Therapeutics Ltd. Enterprise Value-to-Revenue Ratio (07/04/2022 - 11/20/2026)

CYTO (Altamira Therapeutics Ltd.): analytical breakdowns and indicator data

- share price and expert price forecast:
- business market valuation indicators:
Fundamental company valuation:CYTO - Altamira Therapeutics
Original product of altamiratherapeutics.com

To build a resilient portfolio, I utilize EV/Sales, which compares the total enterprise value of a business to its revenue, eliminating the impact of debt to determine the actual price of one dollar of sales. Amid geopolitical risks hindering the clinical trials of Altamira Therapeutics (CYTO), the EV/Sales multiple trajectory clearly demonstrates the extent to which market expectations are outpacing the company's current operational efficiency.

Direct competitors

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Company Value to Revenue SNYR|Enterprise Value-to-Revenue Multiple rallybio.com RLYB|EV/Sales Multiple LEXX|PULM (Pulmatrix, Inc.) - Business Value to Revenue|Pheton Holdings - Company Value to Revenue|EV/Sales Multiple Aptorum Group Limited APM|LYRA: Company Value to Revenue|IBO: Enterprise Value-to-Revenue Ratio|TNFA: EV/Sales Multiple|YCBD: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio PainReform Ltd|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio